Leveraging an agreement with a leading European sensor developer, Zenosense is developing a novel device that detects Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, commonly referred to as “staph.” The company intends to market the developed product primarily to hospitals to combat healthcare-associated infections (HAIs).
The Centers for Disease Control and Prevention (CDC) estimate that one in every 20 patients treated in U.S. hospitals develop an HAI, which are directly responsible for at least 23,000 deaths per year in the United States alone.
Industry figures estimate the annual costs of treating hospitalized MRSA patients specifically to be between $3.2 billion and $4.2 billion in the United States alone. Infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.
The Zenosense MRSA detection device, which is being exclusively developed by Sgenia Group through their subsidiary Zenon Biosystem, is designed to function like a “smoke detector” for MRSA. The device is expected to detect MRSA in the environment, such as a hospital setting, or infected patient, even before a patient demonstrates any obvious symptoms.
Utilizing established Sgenia programming and patent-pending hardware, the Zenosense detector utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of “virtual sensors.”
Upon final product development, the Zenosense device may be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting, addressing this dire unmet medical need. Recent studies suggest that implementing prevention practices can slash occurrence of HAIs by an astounding 70%, saving between $25.0 billion and $31.5 billion in medical cost savings in the United States.
For more information visit www.zenosense.net
Let us hear your thoughts: Zenosense, Inc. Message Board